Bloomberg Intelligence
OPKO's Bishop on FDA Approval Of Its Kidney Disease Drug(Audio)
This episode isn’t summarized yet
Create a free account and summarize it. In a few minutes you’ll have the key takeaways and a section-by-section summary.
Show notes
(Bloomberg) -- Taking Stock with Kathleen Hays and Pimm Fox. GUEST: Dr. Charles Bishop, CEO of OPKO Health Renal Division, to discuss the FDA’s approval of Rayaldee and the health issues surrounding chronic kidney disease
See omnystudio.com/listener for privacy information.